The molecular cloning of AT1 and AT2 receptors, and the development of Ang II receptor blockers (ARBs) for treatment of hypertension, diabetic nephropathy, and other kidney diseases represent one of the most significant breakthroughs in the Ang II receptor research field over last 3 decades. This evidence concerns the gene AGTR1 and hypertensive disorder.